
## **Ronald M Krauss**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2987998/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Identifying genetic modulators of statin response using subject-derived lymphoblastoid cell lines. Pharmacogenomics, 2021, 22, 413-421.	0.6	1
2	Fecal Microbiome Composition Does Not Predict Dietâ€Induced TMAO Production in Healthy Adults. Journal of the American Heart Association, 2021, 10, e021934.	1.6	14
3	Public health guidelines should recommend reducing saturated fat consumption as much as possible: NO. American Journal of Clinical Nutrition, 2020, 112, 19-24.	2.2	37
4	Public health guidelines should recommend reducing saturated fat consumption as much as possible: Debate Consensus. American Journal of Clinical Nutrition, 2020, 112, 25-26.	2.2	34
5	Public health guidelines should recommend reducing saturated fat consumption as much as possible: YES. American Journal of Clinical Nutrition, 2020, 112, 13-18.	2.2	67
6	Lessons Learned from the POUNDS Lost Study: Genetic, Metabolic, and Behavioral Factors Affecting Changes in Body Weight, Body Composition, and Cardiometabolic Risk. Current Obesity Reports, 2019, 8, 262-283.	3.5	26
7	Effects of red meat, white meat, and nonmeat protein sources on atherogenic lipoprotein measures in the context of low compared with high saturated fat intake: a randomized controlled trial. American Journal of Clinical Nutrition, 2019, 110, 24-33.	2.2	100
8	Effects of a very high saturated fat diet on LDL particles in adults with atherogenic dyslipidemia: A randomized controlled trial. PLoS ONE, 2017, 12, e0170664.	1.1	75
9	The early years of lipoprotein research: from discovery to clinical application. Journal of Lipid Research, 2016, 57, 1771-1777.	2.0	28
10	Which cheese to choose?. American Journal of Clinical Nutrition, 2016, 104, 953-954.	2.2	2
11	Comparison of the DASH (Dietary Approaches to Stop Hypertension) diet and a higher-fat DASH diet on blood pressure and lipids and lipoproteins: a randomized controlled trial. American Journal of Clinical Nutrition, 2016, 103, 341-347.	2.2	240
12	Saturated Fats Versus Polyunsaturated Fats Versus Carbohydrates for Cardiovascular Disease Prevention and Treatment. Annual Review of Nutrition, 2015, 35, 517-543.	4.3	203
13	Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition. Circulation, 2015, 132, 1648-1666.	1.6	152
14	Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin. Journal of Clinical Lipidology, 2015, 9, 93-102.	0.6	23
15	Diets High in Protein or Saturated Fat Do Not Affect Insulin Sensitivity or Plasma Concentrations of Lipids and Lipoproteins in Overweight and Obese Adults. Journal of Nutrition, 2014, 144, 1753-1759.	1.3	29
16	Comparison of four methods of analysis of lipoprotein particle subfractions for their association with angiographic progression of coronary artery disease. Atherosclerosis, 2014, 233, 713-720.	0.4	81
17	Pharmacometabolomics of Statin Response. Clinical Pharmacology and Therapeutics, 2013, 94, 562-565.	2.3	44
18	Levels of Cholesterol in Small LDL Particles Predict Atherosclerosis Progression and Incident CHD in the HDL-Atherosclerosis Treatment Study (HATS), PLoS ONE, 2013, 8, e56782.	1.1	31

RONALD M KRAUSS

#	Article	IF	CITATIONS
19	RHOA Is a Modulator of the Cholesterol-Lowering Effects of Statin. PLoS Genetics, 2012, 8, e1003058.	1.5	32
20	Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib. Journal of Lipid Research, 2012, 53, 540-547.	2.0	83
21	Metabolomics Reveals Amino Acids Contribute to Variation in Response to Simvastatin Treatment. PLoS ONE, 2012, 7, e38386.	1.1	90
22	Changes in Atherogenic Dyslipidemia Induced by Carbohydrate Restriction in Men Are Dependent on Dietary Protein Source. Journal of Nutrition, 2011, 141, 2180-2185.	1.3	27
23	Coordinately Regulated Alternative Splicing of Genes Involved in Cholesterol Biosynthesis and Uptake. PLoS ONE, 2011, 6, e19420.	1.1	55
24	Acute Overactive Endocannabinoid Signaling Induces Glucose Intolerance, Hepatic Steatosis, and Novel Cannabinoid Receptor 1 Responsive Genes. PLoS ONE, 2011, 6, e26415.	1.1	22
25	Enteric Microbiome Metabolites Correlate with Response to Simvastatin Treatment. PLoS ONE, 2011, 6, e25482.	1.1	172
26	Lipoprotein subfractions and cardiovascular disease risk. Current Opinion in Lipidology, 2010, 21, 305-311.	1.2	216
27	Saturated Fatty Acids and Risk of Coronary Heart Disease: Modulation by Replacement Nutrients. Current Atherosclerosis Reports, 2010, 12, 384-390.	2.0	289
28	Genome-Wide Association of Lipid-Lowering Response to Statins in Combined Study Populations. PLoS ONE, 2010, 5, e9763.	1.1	205
29	What can the genome tell us about LDL cholesterol?. Lancet, The, 2008, 371, 450-452.	6.3	12
30	Variation in the 3-Hydroxyl-3-Methylglutaryl Coenzyme A Reductase Gene Is Associated With Racial Differences in Low-Density Lipoprotein Cholesterol Response to Simvastatin Treatment. Circulation, 2008, 117, 1537-1544.	1.6	144
31	Increased plasma concentrations of lipoprotein(a) during a low-fat, high-carbohydrate diet are associated with increased plasma concentrations of apolipoprotein C-III bound to apolipoprotein B–containing lipoproteins. American Journal of Clinical Nutrition, 2007, 85, 1527-1532.	2.2	36
32	Separate effects of reduced carbohydrate intake and weight loss on atherogenic dyslipidemia. American Journal of Clinical Nutrition, 2006, 83, 1025-1031.	2.2	277
33	Influence of dietary carbohydrate and fat on LDL and HDL particle distributions. Current Atherosclerosis Reports, 2005, 7, 455-459.	2.0	70
34	Dietary and Genetic Probes of Atherogenic Dyslipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2265-2272.	1.1	111